Skip to main content
SpringerLink
Log in

Serum alpha 1 antitrypsin potent act as an early diagnostic biomarker for cardiac amyloidosis

  • Original Article
  • Published:
Heart and Vessels Aims and scope Submit manuscript

Abstract

Cardiac amyloidosis is a refractory cardiomyopathy with a poor prognosis and lacks effective treatments. N-terminal pro-brain natriuretic peptide (NT-proBNP) and troponin T are poor prognostic factors for myocardial amyloidosis. However, NT-proBNP and troponin also serve as markers of heart failure and myocardial infarction, lacking specificity. Whether abnormal elevation of alpha-1 antitrypsin in myocardial amyloidosis also predicts the poor prognosis of patients remains unknown. We conducted a retrospective single-center case–control study to analyze the serological and physical examination data of 83 cardiac amyloidosis patients and 68 healthy controls matched by gender and age. We aimed to explore the onset and prognostic factors of cardiac amyloidosis. The serum alpha-1 antitrypsin level (169.78 ± 39.59 mg/dl) in patients with cardiac amyloidosis was significantly higher than that in the normal control (125.92 ± 18.26 mg/dl). Logistic regression results showed that alpha-1 antitrypsin, free sialic acid, high-density lipoprotein cholesterol, apolipoprotein A/B ratio, and homocysteine were predictors of cardiac amyloidosis. Multivariable logistic regression showed that only alpha 1 antitrypsin was an independent risk factor for cardiac amyloidosis. Receiver operating characteristic curve analysis based on the Mayo stage and troponin level showed the cut-off value of 140.55 mg/dl for alpha-1 antitrypsin in predicting cardiac amyloidosis with 81.7% sensitivity and 83.9% specificity. Elevated alpha-1 antitrypsin levels may be an early diagnostic biomarker for cardiac amyloidosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Bhogal S, Ladia V, Sitwala P, Cook E, Bajaj K, Ramu V, Lavie CJ, Paul TK (2018) Cardiac amyloidosis: an updated review with emphasis on diagnosis and future directions. Curr Probl Cardiol 43(1):10–34

    Article  PubMed  Google Scholar 

  2. Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Plante-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M, Brannagan TH 3rd, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Conceicao I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, McEvoy BW, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 379(1):22–31

    Article  CAS  PubMed  Google Scholar 

  3. Aimo A, Buda G, Fontana M, Barison A, Vergaro G, Emdin M, Merlini G (2018) Therapies for cardiac light chain amyloidosis: an update. Int J Cardiol 271:152–160

    Article  PubMed  Google Scholar 

  4. Manwani R, Hegenbart U, Mahmood S, Sachchithanantham S, Kyriakou C, Yong K, Popat R, Rabin N, Whelan C, Dittrich T, Kimmich C, Hawkins P, Schonland S, Wechalekar A (2018) Deferred autologous stem cell transplantation in systemic AL amyloidosis. Blood Cancer J 8(11):101

    Article  PubMed  PubMed Central  Google Scholar 

  5. Gertz MA (2020) Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment. Am J Hematol 95(7):848–860

    Article  CAS  PubMed  Google Scholar 

  6. Sperry BW, Reyes BA, Ikram A, Donnelly JP, Phelan D, Jaber WA, Shapiro D, Evans PJ, Maschke S, Kilpatrick SE, Tan CD, Rodriguez ER, Monteiro C, Tang WHW, Kelly JW, Seitz WH Jr, Hanna M (2018) Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release. J Am Coll Cardiol 72(17):2040–2050

    Article  PubMed  Google Scholar 

  7. Ikram A, Donnelly JP, Sperry BW, Samaras C, Valent J, Hanna M (2018) Diflunisal tolerability in transthyretin cardiac amyloidosis: a single center’s experience. Amyloid 25(3):197–202

    Article  CAS  PubMed  Google Scholar 

  8. Hu K, Liu D, Salinger T, Oder D, Knop S, Ertl G, Weidemann F, Frantz S, Stork S, Nordbeck P (2018) Value of cardiac biomarker measurement in the differential diagnosis of infiltrative cardiomyopathy patients with preserved left ventricular systolic function. J Thorac Dis 10(8):4966–4975

    Article  PubMed  PubMed Central  Google Scholar 

  9. Lo Presti S, Mihos CG, Yucel E, Horvath SA, Santana O (2017) A focused review on the pathophysiology, diagnosis, and management of cardiac amyloidosis. Rev Cardiovasc Med 18(4):123–133

    Article  PubMed  Google Scholar 

  10. Migrino RQ, Harmann L, Christenson R, Hari P (2014) Clinical and imaging predictors of 1-year and long-term mortality in light chain (AL) amyloidosis: a 5-year follow-up study. Heart Vessels 29(6):793–800

    Article  PubMed  Google Scholar 

  11. Swiger KJ, Friedman EA, Brittain EL, Tomasek KA, Huang S, Su YR, Sawyer DB, Lenihan DJ (2016) Plasma hepatocyte growth factor is a novel marker of AL cardiac amyloidosis. Amyloid 23(4):242–248

    Article  CAS  PubMed  Google Scholar 

  12. Sattianayagam PT, Lane T, Fox Z, Petrie A, Gibbs SD, Pinney JH, Risom SS, Rowczenio DM, Wechalekar AD, Lachmann HJ, Gilbertson JA, Hawkins PN, Gillmore JD (2013) A prospective study of nutritional status in immunoglobulin light chain amyloidosis. Haematologica 98(1):136–140

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Ye L, Shi H, Wu HM, Wang FY (2016) Primarily isolated hepatic involvement of amyloidosis: a case report and overview. Medicine (Baltimore) 95(52):e5645

    Article  PubMed  Google Scholar 

  14. Richter K, Amati AL, Padberg W, Grau V (2022) Negative regulation of ATP-induced inflammasome activation and cytokine secretion by acute phase proteins: a mini review. Front Pharmacol 13:981276

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, Laumann K, Zeldenrust SR, Leung N, Dingli D, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Gertz MA (2012) Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 30(9):989–995

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Palladini G, Milani P, Merlini G (2020) Management of AL amyloidosis in 2020. Blood 136(23):2620–2627

    Article  CAS  PubMed  Google Scholar 

  17. Mota A, Sahebghadam Lotfi A, Jamshidi AR, Najavand S (2014) Alpha 1-antitrypsin activity is markedly decreased in Wegener’s granulomatosis. Rheumatol Int 34(4):553–558

    Article  CAS  PubMed  Google Scholar 

  18. Turhan Caglar FN, Ksanski V, Polat V, Ungan I, Kural A, Ciftci S, Demir B, Ugurlucan M, Akturk F, Karakaya O (2016) The association between alpha1-antitrypsin and coronary artery ectasia. Angiology 67(10):927–931

    Article  PubMed  Google Scholar 

  19. Eriksson S, Janciauskiene S, Merlini G (1995) The putative role of alpha-1-antitrypsin in the disaggregation of amyloid lambda fibrils. J Intern Med 237(2):143–149. https://doi.org/10.1111/j.1365-2796.1995.tb01154.x

    Article  CAS  PubMed  Google Scholar 

  20. Edgar RG, Patel M, Bayliss S, Crossley D, Sapey E, Turner AM (2017) Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review. Int J Chron Obstruct Pulmon Dis 12:1295–1308

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Curjuric I, Imboden M, Bettschart R, Caviezel S, Dratva J, Pons M, Rothe T, Schmidt-Trucksass A, Stolz D, Thun GA, von Eckardstein A, Kronenberg F, Ferrarotti I, Probst-Hensch NM (2018) Alpha-1 antitrypsin deficiency: from the lung to the heart? Atherosclerosis 270:166–172

    Article  CAS  PubMed  Google Scholar 

  22. Lubrano V, Vergaro G, Maltinti M, Ghionzoli N, Emdin M, Papa A (2020) alpha-1 Antitrypsin as a potential biomarker in chronic heart failure. J Cardiovasc Med (Hagerstown) 21(3):209–215

    Article  CAS  PubMed  Google Scholar 

  23. Sharma S, Sarkar S, Choudhury C, Singh L, Singh H, Chakraborti A (2023) Alpha-1-antitrypsin in serum exosomes and pericardial fluid exosomes is associated with severity of rheumatic heart disease. Mol Cell Biochem 478(6):1383–1396

    Article  CAS  PubMed  Google Scholar 

  24. Jedicke N, Struever N, Aggrawal N, Welte T, Manns MP, Malek NP, Zender L, Janciauskiene S, Wuestefeld T (2014) alpha-1-antitrypsin inhibits acute liver failure in mice. Hepatology 59(6):2299–2308

    Article  CAS  PubMed  Google Scholar 

  25. Berger M, Liu M, Uknis ME, Koulmanda M (2018) Alpha-1-antitrypsin in cell and organ transplantation. Am J Transplant 18(7):1589–1595

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Migrino RQ, Hari P, Gutterman DD, Bright M, Truran S, Schlundt B, Phillips SA (2010) Systemic and microvascular oxidative stress induced by light chain amyloidosis. Int J Cardiol 145(1):67–68

    Article  PubMed  Google Scholar 

  27. Ando Y, Suhr O, El-Salhy M (1998) Oxidative stress and amyloidosis. Histol Histopathol 13(3):845–850

    CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Haitao Yuan and Huiting Qu Contributed equally.

Authors and Affiliations

  1. Department of Cardiac Medicine, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China

    Ye Zhu & Haitao Yuan

  2. Department of Internal Medicine, The Fifth People’s Hospital of Jinan, Jinan, Shandong, China

    Ye Zhu

  3. Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China

    Huiting Qu

  4. Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China

    Huiting Qu

Authors
  1. Ye Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Haitao Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Huiting Qu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Huiting Qu.

Ethics declarations

Conflict of interest

The authors report no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhu, Y., Yuan, H. & Qu, H. Serum alpha 1 antitrypsin potent act as an early diagnostic biomarker for cardiac amyloidosis. Heart Vessels (2024). https://doi.org/10.1007/s00380-024-02396-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00380-024-02396-4

Keywords

Search

Navigation